News Releases
All Releases
View Summary Peregrine Pharmaceuticals Provides Update on Status of Cotara Phase III
Sep 19, 2002
PDF 6.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Grant of Patent for New Vascular Targeting Agents
Sep 17, 2002
PDF 9.4 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Vascular Targeting Agent Platform At the 2002 Antibody World Summit; Company Announces Quarterly Conference Call
Sep 12, 2002
PDF 8.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Receives Notice From Nasdaq to Start 180-Day Grace Period to Regain Compliance with Nasdaq Listing Requirements
Aug 22, 2002
PDF 7.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces $1,856,000 Investment from Institutional Investor; Over $10 Million in Cash and Cash Commitments on Hand; Conference Call Set for 11:00 AM EDT, Aug. 15
Aug 13, 2002
PDF 8.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces $7.1 Million Private Investment Commitment From Institutional Investors
Aug 12, 2002
PDF 9.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Submits Extension to File Its Annual Report On Form 10-K; Quarterly Conference Call To Be Rescheduled
Jul 29, 2002
PDF 7.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals' Quarterly Conference Call Rescheduled for Tuesday, July 30
Jul 24, 2002
PDF 6.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Grant of New Patent for Vascular Targeting Agents
Jul 11, 2002
PDF 9.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on Status of Cotara Phase III and Schedules Quarterly Conference Call
Jul 1, 2002
PDF 7.7 KB Add to Briefcase
View Summary Avid Bioservices to Present At Biologics Manufacturing Conference
Jun 24, 2002
PDF 6.9 KB Add to Briefcase
View Summary Innovative Administration of Peregrine Pharmaceuticals' Radiolabeled TNT Successfully Treats Inoperable Lung Cancer
Jun 19, 2002
PDF 11.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces U.S. Patent Granted for New Cancer Treatment
Jun 18, 2002
PDF 9.1 KB Add to Briefcase
View Summary Patent for Peregrine Pharmaceuticals' Vasopermeation Enhancement Technology Issued
Jun 17, 2002
PDF 8.8 KB Add to Briefcase
View Summary New Class of Anti-Cancer Agents Highlighted At First International Conference On Vascular Targeting
Jun 13, 2002
PDF 10.0 KB Add to Briefcase
View Summary Peregrine's Vascular Targeting Agent Platform Selectively Destroys Blood Supply to Cancer Tumors in an Animal Model
Jun 11, 2002
PDF 9.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Vascular Targeting Agent Technology At BIO 2002
Jun 10, 2002
PDF 10.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Data On Vasopermeation Enhancement Agent Technology At American Society of Clinical Oncology Annual Meeting
May 21, 2002
PDF 10.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Publication of Data Demonstrating Development of Genetically Engineered TNT Antibody Fragments Expressed in Mammalian Cells
May 14, 2002
PDF 9.8 KB Add to Briefcase
View Summary Brain Tumor Action Week Pushes Disease Into Spotlight; Advances in Biotechnology Yield Promising Brain Tumor Treatments
May 7, 2002
PDF 6.4 KB Add to Briefcase
Showing 601-620 of 639 Page: 1 ... 27 28 29 30 31 32  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Print E-mail